Search for: "State v. Bristol-Myers Squibb Company "
Results 61 - 80
of 159
Sorted by Relevance
|
Sort by Date
13 Feb 2015, 12:00 pm
At issue in the case were Bristol-Myers Squibb’s anticoagulant Coumadin and AstraZeneca’s ulcer drugs Prilosec and Nexium. [read post]
3 Apr 2023, 6:00 am
The Court’s ruling clarified its decisions in Bristol-Myers Squibb Co. v. [read post]
25 Apr 2010, 5:52 pm
Bristol-Myers Squibb Co. [read post]
28 Jul 2011, 3:33 pm
207/10, Orifarm v Merck Sharpe & Dohme; Paranova v Merck Sharp & Dohme, sped through in pretty good time. [read post]
10 Nov 2015, 3:41 am
Don’t forget to tune in today for the webcast – “How to Draft Meaningful Sustainability Reports” – to hear Lou Coppola of the Governance & Accountability Institute, Kate Kelly of Bristol-Myers Squibb and Pam Styles of Next Level Investor Relations explain the keys to drafting sustainability reports that are meaningful to investors & other constituents and a “how to” list of things you should be aware of when drafting. [read post]
17 May 2021, 1:12 pm
“And Trimble is headquartered in California, connecting California to Trimble’s claims, which is a consideration the Court in Ford found relevant in distinguishing its earlier decision in Bristol-Myers. [read post]
28 Aug 2018, 12:16 am
Case law states that a brand owner can oppose a repackaging of a pharmaceutical product if the repackaging threatens the guarantee of origin, unless certain conditions are met (as laid out in the cases Bristol-Myers Squibb (see C-427/93, C-429/93 and C-436/93) and Boehringer Ingelheim (see C348/04)). [read post]
25 Mar 2021, 11:33 am
With Specific Jurisdiction, the Court’s recent decision in Bristol-Myers Squibb Co. v. [read post]
15 May 2009, 4:00 am
All rights reserved.In Tice v Bristol-Myers Squibb, No. 07-3977, the U.S. [read post]
25 Apr 2018, 11:50 am
Ct. 746 (2014)—and particularly in light of the Court’s more recent decisions in Bristol-Myers Squibb Co. v. [read post]
24 Jan 2013, 11:49 am
Bristol-Myers Squibb Co., No. 06-6050 (FLW) (D.N.J. [read post]
8 Jun 2023, 7:43 am
Examples of the latter include the Bristol-Myers-Squibb – Celgene merger in 2018, and the Merck-Wyeth merger of 2009. [read post]
17 Feb 2017, 12:21 pm
Bristol-Myers Squibb Co. v. [read post]
4 Dec 2007, 6:33 pm
Bristol-Myers Squibb was the first company to develop and patent a liquid pharmaceutical composition of megestrol acetate and had a patent that taught that stable suspensions of megestrol acetate can be created but that the type and concentration of the surfactant in solution is critical to creating a stable flocculated suspension. [read post]
8 Jun 2023, 7:43 am
Examples of the latter include the Bristol-Myers-Squibb – Celgene merger in 2018, and the Merck-Wyeth merger of 2009. [read post]
7 Nov 2022, 9:01 pm
In Mallory v. [read post]
24 May 2012, 4:23 am
Bristol-Myers Squibb Co., 2011 WL 2784101, at *3 (D.N.J. 2011), the Court did not hold that the warning label was enough to give notice. [read post]
8 Aug 2014, 5:00 am
In Bristol-Myers Squibb Co. v. [read post]
15 May 2014, 11:40 am
I accept that, for the reasons explained by Jacob J in Bristol-Myers Squibb and Lord Hoffmann in Kirin-Amgen, courts should be cautious before relying upon prosecution history as an aid to construction. [read post]
26 May 2015, 7:42 am
Bristol-Myers Squibb Co., 2011 WL 4708850 (D. [read post]
